David J. TaylorSell
Vertex Pharmaceuticals Incorporated - Common Stock · Transaction Aug 26, 2026 · Filed Sep 5, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · VRTX
-1.77% · -$9.01 · Vol Not reported
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Vertex Pharmaceuticals Inc
Biotechnology
$499.74
Follow $VRTX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $VRTX by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredFri Oct 16 · last completed session · Markets closed · resumes Mon 9:30 ET · VRTX
MethodologyVRTX
Vertex Pharmaceuticals Inc
Fri Oct 16 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
66/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Confidence: HIGH · 6 of 6 factors measured · Fri Oct 16 · last completed session · Markets closed · resumes Mon 9:30 ET
AI Analysis
SovereignWhy is VRTX moving today?
Sovereign unlock connects news, insider activity, analyst moves, and available price action.
About Vertex Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
1991
Employees
6K
Country
US
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$511.06
Day high
$512.21
Day low
$497.49
Previous close
$508.75
52W high
$557.96
-10.43% from high
52W low
$409.47
61% of range
Market cap
$126.7B
P/E
28.75×
EPS
$17.19
Beta
0.23
Shares out
253.5M
Avg volume
1.1M
VWAP
$508.75
Last session
Price history computed in-house
1W
-2.03%
1M
-1.69%
3M
+4.00%
1Y
+19.90%
YTD
+10.23%
SMA 50 $522.54 · below
SMA 200 $475.90 · above
52W position 61%
VRTX overview
SEC industry peers
VRTX peers
Related filings and maps
Public disclosures
Congress activity in VRTX
17 filers · 15 buys · 23 sells (2 labeled S (partial)) · May 13, 2015 to Aug 26, 2026 · House 32 / Senate 6
All available history · Latest 5 of 38 lines · Read Oct 18, 2026, 9:12 AM UTC
Official filing ↗
David J. TaylorSell
Vertex Pharmaceuticals Incorporated - Common Stock · Transaction Jan 29, 2026 · Filed Feb 2, 2026 · $1,001 to $15,000
Vertex Pharmaceuticals Incorporated - Common Stock · Transaction Jun 11, 2025 · Filed Aug 13, 2025 · $1,001 to $15,000
Vertex Pharmaceuticals Incorporated - Common Stock · Transaction Jun 10, 2025 · Filed Aug 13, 2025 · $1,001 to $15,000
Jefferson ShreveSell
Vertex Pharmaceuticals Incorporated - Common Stock · Transaction May 12, 2025 · Filed Jun 22, 2025 · $15,001 to $50,000
Federal contracts
VRTX contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for VRTX in this window.
Lobbying spend
VRTX lobbying filings, year to date.
Registered lobbying filings matched to Vertex Pharmaceuticals Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for VRTX in this window.
Analyst ratings
Sovereign unlock shows available analyst consensus for VRTX.